ReviewPLoS neglected tropical diseases2016
Zika Virus: Medical Countermeasure Development Challenges.
Review in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 190 citations in OpenAlex.
- A systematic review and evaluation of Zika virus forecasting and prediction research during a public health emergency of international concern.PLoS neglected tropical diseases · 2019Pooled it
- Synthetic rational design of live-attenuated Zika viruses based on a computational model.Nucleic acids research · 2025Article
- Identification of B-cell epitopes of Indian Zika virus strains using immunoinformatics.Frontiers in immunology · 2025Article
- Public Health Strategies in the Face of Crisis: A Comprehensive Review of the Zika Outbreak in India.Cureus · 2024Review
- Bridging landscape ecology and urban science to respond to the rising threat of mosquito-borne diseases.Nature ecology & evolution · 2022Review
- Zika virus as an emerging arbovirus of international public health concern.Osong public health and research perspectives · 2022Article
- Therapeutic Application of Genome Editing Technologies in Viral Diseases.International journal of molecular sciences · 2022Review
- Targeting Zika Virus with New Brain- and Placenta-Crossing Peptide-Porphyrin Conjugates.Pharmaceutics · 2022Article
- Borderline microscopic organism and lockdown impacted across the borders-global shakers.Environmental science and pollution research international · 2022Review
- New self-sexingFrontiers in bioengineering and biotechnology · 2022Article
- Silver Nanoparticles as Potential Antiviral Agents.Pharmaceutics · 2021Review
- A Novel Virus ofmSystems · 2021Article
- Aptamers for Anti-Viral Therapeutics and Diagnostics.International journal of molecular sciences · 2021Review
- Parental Stress in Primary Caregivers of Children with Evidence of Congenital Zika Virus Infection in Northeastern Brazil.Maternal and child health journal · 2021Review
- Protein Interaction Network Biology in Neuroscience.Proteomics · 2021Review
- Article
- Zika Virus-Encoded NS2A and NS4A Strongly Downregulate NF-κB Promoter Activity.Journal of microbiology and biotechnology · 2020Article
- An overview of the current medical literature on Zika virus.Biophysical reviews · 2020Article
- The great potential of entomopathogenic bacteria Xenorhabdus and Photorhabdus for mosquito control: a review.Parasites & vectors · 2020Review
- Ribosome Display Technology: Applications in Disease Diagnosis and Control.Antibodies (Basel, Switzerland) · 2020Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 1 country.
Funding
Abstract
introductionReports of high rates of primary microcephaly and Guillain-Barré syndrome associated with Zika virus infection in French Polynesia and Brazil have raised concerns that the virus circulating in these regions is a rapidly developing neuropathic, teratogenic, emerging infectious public health threat. There are no licensed medical countermeasures (vaccines, therapies or preventive drugs) available for Zika virus infection and disease. The Pan American Health Organization (PAHO) predicts that Zika virus will continue to spread and eventually reach all countries and territories in the Americas with endemic Aedes mosquitoes. This paper reviews the status of the Zika virus outbreak, including medical countermeasure options, with a focus on how the epidemiology, insect vectors, neuropathology, virology and immunology inform options and strategies available for medical countermeasure development and deployment.
methodsMultiple information sources were employed to support the review. These included publically available literature, patents, official communications, English and Lusophone lay press. Online surveys were distributed to physicians in the US, Mexico and Argentina and responses analyzed. Computational epitope analysis as well as infectious disease outbreak modeling and forecasting were implemented. Field observations in Brazil were compiled and interviews conducted with public health officials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.